Illinois News Desk

DelveInsight Business Research LLP

DelveInsight’s “Prediabetes Market Insights, Epidemiology, and Market Forecast-2032“ report delivers an in-depth understanding of the Prediabetes, historical and forecasted epidemiology, and the Prediabetes market trends in the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Prediabetes Overview

According to the Centers for Disease Control and Prevention, prediabetes is a serious health condition where blood sugar levels are higher than normal but not high enough to get diagnosed easily as type 2 diabetes. Prediabetes is also commonly referred to as borderline diabetes, which is a metabolic condition and a growing global problem closely related to obesity. Prediabetes can increase the risk of developing type 2 diabetes, heart disease, and stroke. Prediabetes is caused due to the cells in the body that do not normally respond to insulin, thus leading the pancreas to produce excess insulin so that cells can respond. Eventually, the pancreas cannot keep up, and blood sugar rises, setting the stage for prediabetes and type 2 diabetes in the long run.

 Prediabetes  Epidemiology Insights

• Prediabetes had a prevalence of 96 million among adults in the US in 2019, which accounted for 38% of the entire US adult population. Of these cases, 26.4 million people aged 65 years or older, signifying a 48.8% prevalence in that particular age group. A higher percentage of men (41.0%) than women (32.0%) had prediabetes based on their fasting glucose or A1C level. Overall awareness of patients having this condition was 19% in the period 2017–2020. And although there were no significant changes in the prevalence rate of prediabetes, the awareness of having this condition increased in adults.

• As per Hostalek (2019), prediabetes progresses to type-2 diabetes in approximately 25% of subjects within 3–5 years, and as many as 70% of individuals with prediabetes will develop overt diabetes within their lifetime.

• As per Lailler et al. (2020), prediabetes had a prevalence of 11% in England, 20.8% in Germany, 28.6% in France in 2014–2016, according to ADA criteria. France had a prediabetes prevalence of 9.9%, according to WHO criteria.

• According to the United States-based study by Mainous et al., the prevalence of prediabetes among healthy-weight adults aged 20 years and older and without diagnosed or undiagnosed diabetes increased from 10.2% in 1988–1994 to 18.5% in 2012. Also, among individuals aged 45 years and older, the prevalence of prediabetes increased from 22.0% to 33.1%.

Click here to learn more about the Prediabetes Market Landscape

The Report Covers the Prediabetes Epidemiology Segmented by:

• Prediabetes gender-specific cases 

• Prediabetes prevelant cases 

• Prediabetes-diagnosed prevalent cases 

• Prediabetes treated cases  

Prediabetes Market Outlook 

The Prediabetes market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Prediabetes market trends by analyzing the impact of current Prediabetes therapies on the market, unmet needs, drivers, barriers, and demand for better technology. This segment gives a thorough detail of the Prediabetes market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Prediabetes market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, the Prediabetes market in 7MM is expected to witness a major change in the study period 2019-2032.

Prediabetes Key Companies working on it 

• Novartis 

• Corcept Therapeutics 

• Boehringer Inghelium

And many others 

 Prediabetes Therapies Covered and Analyzed in the Report:

•  RRx-001 

•  Temozolomide 

•  PF-06840003

•  OKN-007

And many others 

Learn more about the Key Companies and Emerging Therapies in the Oligodendroglioma Market.

 Table of Contents 

1. Key Insights 

2. Prediabetes Introduction 

3. Executive Summary of Prediabetes   

4. Disease Background and Overview

5. Epidemiology and patient population

6. Prediabetes Emerging Therapies

7. Prediabetes Market Outlook

8. Market Access and Reimbursement of Therapies

9. Market Drivers 

10. Market Barriers 

11. Appendix

12. Report Methodology

13. DelveInsight Capabilities

14. Disclaimer

Learn about the detailed offerings of the report @ Prediabetes Market Outlook.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/